Reciprocal Impact of Molnupiravir and Favipiravir Monocomponents of the Combination Drug on Each Other's Pharmacokinetics in a Phase I Clinical Trial
Introduction. COVID-19 (Coronavirus disease 2019) almost 4 years after he start of the pandemic is still a significant public health problem. SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) that causes COVID-19 continues to mutate and spread throughout the world. Molnupiravir and favipi...
Zapisane w:
| Główni autorzy: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Russo |
| Wydane: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2024-03-01
|
| Seria: | Разработка и регистрация лекарственных средств |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.pharmjournal.ru/jour/article/view/1770 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|